Seeking Alpha

Proactive Investor's  Instablog

Proactive Investor
Send Message
Proactiveinvestors is a leading multimedia news organization, investor portal and events management business with offices in New York, Sydney, Toronto and London. Proactiveinvestors operates five financial websites in four languages providing breaking news, comment and analysis on hundreds of... More
My company:
Proactiveinvestors
My blog:
Proactiveinvestors
View Proactive Investor's Instablogs on:
  • Regeneus To Start Personalised Human Cancer Vaccine Trial

    Regeneus' (ASX:RGS) receipt of ethics approval will see a start to the first-in-human trial of its promising cancer treatment in Sydney that uses the patient's own tumour to create a personalised cancer vaccine.

    RGSH4K is produced from a patient's own cancer cells and combined with a proprietary immunostimulant, to stimulate the immune system.

    The trial has its genesis in promising results during canine trials, where the majority of treated dogs outliving the average expected survival time for their particular type of cancer.

    It is expected to demonstrate that this personalised treatment is relevant to primary and secondary tumours and will reduce the risk of tumour recurrence.

    This has the potential to target a wide range of hard-to-treat cancers with a single product.

    The ACTIVATE trial, is a single centre, open label, first in-human, Phase 1 dose escalating study to evaluate the safety, tolerability and preliminary efficacy of RGSH4K, administered in 21 patients with advanced cancers.

    Participants in the trial will need to have stored a tumour sample stored in Regeneus' ethics-approved tumour bank. This may be used to produce an autologous cancer vaccine for individual patient's use in the trial.

    The principal investigators for the trial are leading medical oncologists, Professor Stephen Clarke and Associate Professor Nick Pavlakis from University of Sydney's Northern Clinical School at the Kolling Institute of Medical Research located at Royal North Shore Hospital in St Leonards, Sydney.

    The trial will be conducted through the Northern Cancer Institute in St Leonards.

    "We are hopeful that the success we have seen with the vaccine in treating a wide variety of cancers in dogs translates to humans," chief executive officer John Martin said.

    RGSH4K cancer vaccine

    RGSH4K was developed at the Bill Walsh Translational Cancer Research Laboratory which is part of the Kolling Institute of Medical Research and is the research arm of the Medical Oncology Department, Royal North Shore Hospital.

    It is designed to activate the immune system against the cancer cells to initiate a body-wide response. The immune system's memory should recognise and respond to both existing and new tumours.

    Cancer immunotherapies represent a treatment option without many of the side effects of standard chemotherapy.

    Vaccines interfere minimally with most chemotherapeutic drugs making them likely helping agents to traditional therapies.

    In addition, the RGSH4K vaccine is simple to manufacture and contains no live cancer cells.

    Cancer Vaccine Trial

    In this trial, adult patients with a variety of advanced cancer types will be treated using RGSH4K. The process will work as follows:

    - Suitable patients will have their tumour removed and stored (known as tumour banking) prior to commencing first-line treatment;
    - If the patient relapses, and there are no other useful treatment options available, they will move into the next stage of the trial and, using their excised tumour, have a personalised vaccine produced;
    - The personalised, or autologous vaccine, will be injected at staged intervals and patients monitored for a response.

    The aim will be for the cancer to be stabilised and the tumour to shrink. Ideally this would then lead to an extended life expectancy for the patient, similar to the results obtained in the canine research.

    Analysis

    The upcoming and likely closely-watched Phase 1 in-human clinical trial for the RGSH4K personalised human cancer vaccine is an exciting and key step in Regeneus' push into the emerging immuno-oncology market.

    Highlighting the potential of this sector, a July 2014 report on Sfgate.com, citing industry analysts at Citi, predicted that cancer vaccines and other "emerging immunotherapies" would be worth US$35 billion by 2023.

    While the key focus will be to monitor the safety of the vaccine, the trial will also allow Regeneus to assess the treatment for preliminary efficacy.

    That the vaccine has in canine trials, resulted in the majority of treated dogs outliving the average expected survival time for their particular type of cancer, is promising.

    Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

    May 25 9:29 PM | Link | Comment!
  • Yellow Rock Resources: Gabanintha Vanadium Among Highest Grade

    Yellow Rock Resources (ASX:YRR) shares are expected to climb this morning following some very impressive drilling results at its Gabanintha Project near Meekatharra in Western Australia.

    Initial results from the first 10 reverse circulation drill holes conform the existence high-grade vanadium with new grades of 1.36% vanadium over widths up to 12 metres.

    News flow will be rapid with another 53 holes to come.

    The latest highlights include:

    - 34 metres at 0.77% vanadium from 86 metres, including 8 metres at 1.29% vanadium;
    - 16 metres at 1.31% vanadium from 12 metres;
    - 12 metres at 1.36% vanadium from 36 metres;
    - 13 metres at 1.24% vanadium from 77 metres; and
    - 17 metres at 0.87% vanadium from 84 metres, including 9 metres at 1.17% vanadium.

    The new results are supported by historical drilling results confirm Gabanintha's position as one of the highest grade vanadium deposits currently being advanced globally.

    The high-grade vanadium is contained within a "massive" magnetite zone.

    The zone has been identified along the entire 2 kilometre stretch of the current detailed drilling program, which has been completed at 75 metre line spacing.

    Yellow Rock chief executive Vincent Algar commented:

    "Results received so far support our belief that we have one of the world's highest grade vanadium deposits.

    "The professional quality of the work completed by our contractors to date puts us in an excellent position on the path to develop the project".

    News flow

    Results from another 53 reverse circulation will flow through over the coming weeks.

    Additional upcoming catalysts include metallurgical testing and an updated resource estimation. Pit optimisation / mining studies will commence on receipt of all assay results.

    Currently 167 historical drill holes support an Inferred Resource of 125 million tonnes at 0.70% vanadium, 8.64%TiO2 and 32.6% iron.

    This includes a separate high grade Indicated and Inferred Resource of 60.4 million tonnes at 0.98% vanadium, 11.4% TiO2 and 42.15% iron.

    How Gabanintha is different

    The Gabanintha deposit is an intrusive layered intrusive body smaller, but displaying similar characteristics to the igneous Bushveld Complex, host to some of the world's most significant platinum, vanadium and chromite deposits.

    The deposit is similar to the Windimurra Vanadium Deposit and the Barambie vanadium-titanium deposit located 260 kilometres South and 150 kilometres Southeast of Gabanintha respectively.

    Gabanintha differs from both of these deposits by the consistent presence along strike of the 10 metre thick basal MMZ and the higher overall grade of the Gabanintha Orebody.

    Gabanintha is: 0.98 % vanadium, in MMZ 0.7% vanadium overall, (Windimurra 0.47% vanadium and Barambie 0.82% vanadium).

    The current drillhole grades being observed in new drilling and previously observed in historical drilling compare extremely favourably in tonnage and grade with other high grade deposits globally.

    Namely Largo Resource (TSX:LGO) (1.48% vanadium) and Bushveld Minerals (AIM:BMN) (1.4% vanadium).

    Analysis

    That Gabanintha with today's drill results ranks up there with Largo Resources (NYSE:CVE) with its Maracás Menchen Mine, which has Inferred Resources of 30.4 million tonnes at 0.83% vanadium and a market cap of C$115 million (A$112 million).

    Yellow Rock has a market cap of just $8 million, with a re-rating expected to come following these drilling results.

    The company is leveraged to exploration success, and with results from another 53 holes over coming weeks, Proactive Investors does not expect the current $0.01 share price to remain this modest for long.

    Additional upcoming catalysts include metallurgical testing and an updated resource estimation. Pit optimisation / mining studies will commence on receipt of all assay results.

    Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

    May 25 9:11 PM | Link | Comment!
  • MZI Resources On Track To Be Australia's Next Mineral Sands Producer

    MZI Resources (ASX:MZI) construction of the Keysbrook Project in Western Australia is on-track and on-budget, with the company to become Australia's next mineral sands producer.

    The company is being supported by investors, with its share price of $0.42 around double where the company was valued in mid-December 2014.

    Keysbrook is a high operating profit margin project based on high grade mineral assemblage, and is also a long project with expansion potential.

    Project development is now 51% complete with plant construction and steelwork erection underway at both Keysbrook and Picton sites.

    This puts MZI on schedule for commissioning and first production in Q4 2015, and on-track for first sales in early 2016.

    MZI has recently completed financing and mining equipment supply agreements valued at around $13 million with Komatsu, a Japanese global mining equipment provider.

    Trevor Matthews, managing director for MZI, commented: "Progress for the project continues to be exciting and it's great to see the team working together to deliver a quality project on time and on schedule.

    "The relationship with Komatsu is an important one and a big step towards the commencement of operations, with finance, legal and operations staff working closely on sourcing the mining fleet and bringing together an innovative financing and maintenance arrangement for the site."

    Significantly, MZI already has in place five year binding sales contracts for 85% of annual production, with blue chip counterparties in DuPont (titanium dioxide L88 and L70) and Tricoastal/Wensheng (zircon).

    Komatsu financing agreements

    These agreements provide for the delivery of the mining fleet within the next three months and include ongoing fleet maintenance requirements, as well as providing financing for the mining feed unit (MFU) being constructed by Transmin.

    Key mining equipment, including the primary excavator and entire haulage fleet of three trucks, are already in Komatsu's Perth premises awaiting delivery to site.

    Costs associated with the agreements are captured within existing capital and operating estimates for the Keysbrook project.

    Analysis

    MZI Resources is on-track and on-budget to become Australia's next mineral sands producer from the Keysbrook Project in Western Australia.

    The company is being supported by investors, with its share price of $0.42 around double where the company was valued in mid-December 2014.

    As commissioning moves closer, we expect the share price to continue to track higher, given the IRR and NPV of Keysbrook.

    MZI is on schedule for commissioning and first production in Q4 2015, and on-track for first sales in early 2016.

    The company's chairman Malcolm Randall has also recently been increasing his stake in the company through on-market purchases.

    The project has a Reserve life of 5.5 years and a Resource life of +15 years.

    Recently exploration drilling confirmed extensions to mineralisation, providing the potential to grow Reserves / Resources.

    An updated JORC Resource is expected mid-2015.

    MZI already has in place five year binding sales contracts for 85% of annual production, with blue chip counterparties in DuPont (titanium dioxide L88 and L70) and Tricoastal/Wensheng (zircon).

    Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

    May 25 9:08 PM | Link | Comment!
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.